2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 广东乐心医疗电子股份有限公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2023 年期 初占用资金 余额 2023 年 1-6 月占 累计发生金额 （不含利息） 2023 年 1-6 月占 用资金的利息 （如有） 2023 年 1-6 月 偿还累计发生 金额 2023 年 6 月 30 日占用资金余 额 占用形成原因 占用性质 控股股东、实际控 制人及其附属企业 非经营性占用 非经营性占用 小计 - - - - 前控股股东、实际 控制人及其附属企 业 非经营性占用 非经营性占用 小计 - - - - 其他关联方及附属 企业 非经营性占用 小计 总计 - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算 的会计科目 2023 年期 初占用资金 余额 2023 年 1-6 月占 累计发生金额 （不含利息） 2023 年 1-6 月占 用资金的利息 （如有） 2023 年 1-6 ...

乐心医疗 2023 年公告 关于监事会对2023年限制性股票激励计划激励对象名单的审核意见 及公示情况的说明 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2023 年 07 月 26 日召开了第四届董事会第八次会议、第四届监事会第七次会议，审议通过了《关 于<2023 年限制性股票激励计划（草案）>及其摘要的议案》、《关于<2023 年限制 性股票激励计划实施考核管理办法>的议案》以及《关于核实<2023 年限制性股 票激励计划激励对象名单>的议案》等议案，具体内容详见公司于 2023 年 07 月 27 日披露在巨潮咨询网（www.cninfo.com.cn）的相关内容。 根据《上市公司股权激励管理办法》、《深圳证券交易所创业板上市公司自律 监管指南第 1 号——业务办理》、《深圳证券交易所创业板股票上市规则》等相关 规定，公司监事会对 2023 年限制性股票激励计划（以下简称"本激励计划"） 的激励名单和公示情况进行了核查，相关意见如下： 一、监事会对本激励计划激励名单的审核意见 公司监事会对本激励计 ...

证券代码：300562 证券简称：乐心医疗 广东乐心医疗电子股份有限公司投资者关系活动记录表 编号：2023-001 投资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 ■ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名 称及人员 参与"乐心医疗 2022 年度网上业绩说明会"的投资者 时间 2023 年 05 月 08 日（星期一）下午 15:00-17:00 地点 网上业绩说明会 上市公司接 待人员姓名 董事长、总经理：潘伟潮先生 独立董事：周康先生 董事会秘书：钟玲女士 财务总监：黄林香女士 保荐代表人：桑继春女士 投资者关系 活动主要内 容介绍 本次年度业绩说明会采用网络远程的方式举行，主要就以下内容进行交 流： 一、2022 年度公司情况简介 乐心医疗深耕智能健康领域多年，聚焦远程健康垂直领域，锚定医疗级 远程健康监测设备及服务提供商的战略定位，依托自身在智能医疗健康、智 能可穿戴等领域产品创新研发、产品品质和应用技术等方面的独特优势，将 健康 IoT、大数据与医疗深度融合，形成"健康 IoT+数字健康服务"双轮驱 动的主业布局。 2022 年，公司坚 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 162.61 million, a decrease of 37.55% compared to CNY 260.37 million in the same period last year[7]. - The net profit attributable to shareholders was a loss of CNY 12.10 million, a decline of 1,040.75% from a profit of CNY 1.29 million in the previous year[7]. - The net cash flow from operating activities was negative CNY 13.32 million, a decrease of 130.32% compared to CNY 43.93 million in the same period last year[7]. - Total operating revenue for Q1 2023 was CNY 162.61 million, a decrease of 37.5% compared to CNY 260.37 million in the same period last year[25]. - Net profit for Q1 2023 was a loss of CNY 12.33 million, compared to a profit of CNY 1.11 million in Q1 2022, representing a significant decline[26]. - Cash received from sales of goods and services was CNY 209.41 million, a decrease of 56.0% from CNY 475.52 million in Q1 2022[28]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1.45 billion, down 6.29% from CNY 1.55 billion at the end of the previous year[7]. - Total current assets decreased from CNY 985,129,961.65 at the beginning of the year to CNY 882,135,881.40 at the end of the period, a reduction of approximately 10.5%[21]. - Total liabilities decreased to CNY 465.19 million from CNY 548.46 million, reflecting a reduction of 15.1%[23]. - The total equity attributable to shareholders of the parent company was CNY 998.32 million, down from CNY 1,012.06 million, a decline of 1.4%[23]. - Total current liabilities decreased from CNY 501,323,424.25 to CNY 419,449,687.58, a decrease of approximately 16.3%[22]. Cash Flow - The company reported a net cash outflow from operating activities of CNY 13.32 million, compared to a net inflow of CNY 43.93 million in the previous year[28]. - The net cash flow from investment activities was -230,113,325.71 CNY, compared to a positive cash flow of 47,498,024.77 CNY in the previous year[29]. - Total cash and cash equivalents at the end of the period amounted to 298,020,147.54 CNY, down from 422,592,937.24 CNY at the end of the previous year[29]. - The company experienced a decrease in cash and cash equivalents by 246,910,346.19 CNY during the quarter[29]. - The initial cash and cash equivalents balance was 544,930,493.73 CNY, reflecting a significant liquidity position at the start of the quarter[29]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,642[17]. - The largest shareholder, Pan Weichao, holds 33.57% of shares, totaling 72,066,874 shares, with 55,668,055 shares pledged[17]. - The number of restricted shares held by executives decreased from 61,110,328 to 56,326,453 after unlocking 4,783,875 shares[19]. Operational Focus and Strategy - The company is focusing on optimizing customer and product structure, which has impacted revenue scale during the reporting period[7]. - The company plans to enhance its product competitiveness through advanced technology and expand into emerging markets and diverse sales channels[8]. - The company aims to improve its production and operational situation through cost reduction and efficiency enhancement measures[8]. - The company has not disclosed any new product developments or market expansion strategies in the current report[18]. Financial Expenses and Investments - The company experienced a significant increase in trading financial assets, rising by 354.49% to CNY 270.61 million due to the use of idle funds for bank wealth management products[12]. - The company reported a substantial increase in financial expenses, up 411% to CNY 3.49 million, primarily due to foreign exchange losses from USD-denominated assets[13]. - The company recorded an investment loss of CNY 320.20 thousand, contrasting with a profit of CNY 1.45 million in the previous year[26]. - The company reported a cash inflow from investment activities of 58,672,325.83 CNY, compared to 102,009,190.14 CNY in the previous year[29]. - The company’s cash outflow related to investment activities was significantly higher at 288,785,651.54 CNY compared to the previous year's 54,511,165.37 CNY[29]. Research and Development - Research and development expenses for Q1 2023 were CNY 26.55 million, a decrease of 19.5% from CNY 33.01 million in the same period last year[25]. Audit and Reliability - The report for the first quarter was not audited, indicating potential limitations in the reliability of the financial data presented[30].

广东乐心医疗电子股份有限公司2022年年度报告全文 广东乐心医疗电子股份有限公司 2022 年年度报告 2023-023 【披露时间】 ...

乐心医疗 2023 年公告 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"或"乐心医疗"）《2022 年年度报告》及其摘要已于 2023 年 04 月 28 日刊登于中国证监会指定的创业板 信息披露网站，为了更好地与广大投资者进行交流，使投资者能够进一步了解公 司经营业绩、发展战略等情况，公司将举行 2022 年度网上业绩说明会。 一、会议召开日期和时间 2023 年 05 月 08 日（星期一）下午 15:00-17:00 证券代码：300562 证券简称：乐心医疗 公告编号：2023-037 广东乐心医疗电子股份有限公司 （二）"约调研"平台参与方式： 1、参与方式一：在微信中搜索小程序"乐心医疗投资者关系"参与交流； 乐心医疗 2023 年公告 2、参与方式二：微信扫一扫以下二维码参与交流： 二、会议召开方式及地点 本次业绩说明会将在同花顺路演平台和"约调研"平台采用网络远程的方式 举行。 三、公司出席人员 参加此次网上业绩说明会的公司人员有：董事长潘伟潮先生、 ...

广东乐心医疗电子股份有限公司 2022 年第三季度报告 1 广东乐心医疗电子股份有限公司 2022 年第三季度报告 证券代码：300562 证券简称：乐心医疗 公告编号：2022-092 广东乐心医疗电子股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保 证季度报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 □是 否 2 广东乐心医疗电子股份有限公司 2022 年第三季度报告 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营 ...

Financial Performance - The company's revenue for the first half of 2022 was CNY 541.05 million, a decrease of 32.23% compared to the same period last year[32]. - The net profit attributable to shareholders for the same period was CNY 6.87 million, down 66.48% year-on-year[32]. - The net cash flow from operating activities improved significantly, reaching CNY -15.06 million, an 85.61% increase compared to the previous year[32]. - Research and development expenses totaled CNY 69.17 million, accounting for 12.78% of revenue, which is a 14.32% increase year-on-year[33]. - The company's gross profit margin increased by 5.1% compared to the previous year, indicating improved cost structure management[33]. - Total assets at the end of the reporting period were CNY 1.54 billion, a decrease of 14.15% from the end of the previous year[32]. - The net assets attributable to shareholders were CNY 1.07 billion, reflecting a slight increase of 1.10% compared to the previous year[32]. - Basic earnings per share decreased by 70.00% to CNY 0.03 per share[32]. - The company's operating revenue for the current period was ¥541,048,823.31, a decrease of 32.23% compared to the same period last year, primarily due to strategic adjustments in response to global economic changes[104]. - Operating costs decreased by 36.46% to ¥416,673,585.77, mainly attributed to the decline in operating revenue[104]. - The company reported a significant increase in other income by 144.28% to ¥7,181,801.61, primarily from government subsidies[109]. Strategic Focus and Goals - The company is focusing on enhancing its management capabilities to match its rapid growth and strategic goals in becoming a world-class health IoT and digital health service provider[8]. - The strategic focus remains on becoming a world-class provider of health IoT and digital health services[33]. - The company aims to enhance its global competitiveness by focusing on remote healthcare, home healthcare, and chronic disease management[33]. - The company aims to strengthen its market presence and increase product market share through improved product value and competitive capabilities[9]. - The company is committed to continuous innovation and development of new technologies in the healthcare sector[84]. - The company plans to strengthen its product value and competitive capabilities to improve market share and overall profitability in overseas markets[133]. - The company aims to enhance user engagement and market share through big data analysis and AI technology in health management[45]. Research and Development - The company is committed to increasing R&D investment to improve product technology and develop more user-friendly and differentiated products[11]. - The company emphasizes independent research and development, ensuring product quality and intellectual property rights[45]. - The company has achieved self-research and production capabilities in core components such as sensors and algorithms, enhancing its innovation capacity in biological signal sensing[91]. - The company has built a multi-device collaborative computing framework with its own IoT operating system, focusing on data-driven and open platform strategies[91]. - The company has completed one new patent application related to remote health management technology and one utility model patent for voice-interactive scales[73]. - The company holds a total of 545 patents, including 95 invention patents, 209 utility model patents, and 241 design patents[94]. Market Conditions and Risks - The company faces significant risks from international market fluctuations, particularly in developed regions like Europe, the US, Japan, and South Korea, where export revenue constitutes a large portion of total income[9]. - Rising costs of raw materials and labor pose a challenge to the company's cost control, which could negatively impact profitability[12]. - The health IoT and remote health management market in China is projected to exceed 4 trillion yuan by 2030, driven by population growth and increased health awareness[56]. - The global remote health management market is expected to reach 185.7 billion USD by 2026, indicating a strong growth trajectory[56]. - The aging population is driving the demand for chronic disease management, necessitating the development of comprehensive health management systems[64]. Product Development and Innovation - The company has developed a digital sports management system for schools, utilizing wearable devices to monitor students' health metrics[50]. - The company has established a digital health management solution that integrates IoT and digital health services, covering multiple industries such as insurance and education[47]. - The health IoT product line includes a comprehensive range of monitoring devices, with several products certified as Class II medical devices[43]. - The company has successfully launched a remote blood pressure management system, which includes a health management system for real-time data upload and visualization, now in mass production[71]. - Wearable devices have been developed to monitor health metrics such as heart rate and activity levels, with a focus on improving lifestyle habits, and the system design has been completed for mass production in 2022[71]. - The company has developed a new generation of ECG smart watches, integrating multiple functions and establishing a robust hardware platform for future wearable products[73]. Financial Management and Investments - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[14]. - The company has proposed to delay the investment projects related to the production base and R&D center due to not meeting the planned progress[121]. - The company has not allocated any funds to the projects that have not reached the planned progress or expected benefits[121]. - The company has invested a total of 190 million yuan in bank financial products using idle fundraising for cash management, all of which have been redeemed by the end of the reporting period[125]. - The total amount of raised funds was RMB 59.46 million, with RMB 4.01 million invested during the reporting period and a cumulative investment of RMB 31.45 million[120]. Corporate Governance and Compliance - The company has experienced changes in its board of directors, with several members resigning and new members being elected during the reporting period[143]. - The semi-annual financial report was not audited[171]. - The company has no outstanding guarantees to external parties, and no guarantees were approved during the reporting period[189]. - The company has no significant penalties or rectifications reported during the period[175]. - The company actively participates in social welfare activities, including support for disabled employees[161]. Community Engagement and Sustainability - The company actively promotes energy conservation and emission reduction, aligning with national "dual carbon" policies[156]. - The company provided various types of employment positions to alleviate employment pressure during the global pandemic and unstable environment[160]. - The company supported local Red Cross initiatives and organized employee participation in blood donation activities, contributing to community welfare[161]. - The company is committed to sustainable development and promoting energy conservation among employees[162].

Financial Performance - The company's revenue for Q1 2022 was CNY 260,374,797.52, a decrease of 28.79% compared to CNY 365,624,197.46 in the same period last year[5] - Net profit attributable to shareholders was CNY 1,286,018.55, down 90.09% from CNY 12,978,298.10 year-on-year[5] - Total operating revenue for Q1 2022 was CNY 260.37 million, a decrease of 28.7% compared to CNY 365.62 million in the same period last year[25] - Total operating costs for Q1 2022 were CNY 268.60 million, down 25.2% from CNY 358.98 million year-over-year[25] - Net profit for Q1 2022 was CNY 1.11 million, a significant decline of 88.6% from CNY 9.71 million in Q1 2021[26] - The company reported a total comprehensive income of CNY 1.07 million for Q1 2022, compared to CNY 9.65 million in the same quarter last year[27] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.01, down from CNY 0.07 in Q1 2021[27] Cash Flow - The net cash flow from operating activities increased significantly by 939.45%, reaching CNY 43,925,115.81, compared to a negative cash flow of CNY -5,232,595.94 in the previous year[14] - The net cash flow from operating activities for Q1 2022 was ¥43,925,115.81, a significant improvement compared to a net outflow of ¥5,232,595.94 in Q1 2021[30] - Total cash inflow from investment activities was ¥102,009,190.14, compared to ¥39,257,480.00 in the same period last year, resulting in a net cash flow from investment activities of ¥47,498,024.77, up from ¥14,096,783.38[30] - The net cash flow from financing activities was ¥2,266,206.31, a decrease from ¥370,393,135.70 in Q1 2021, primarily due to lower cash inflow from investment[31] - The total cash outflow for operating activities was ¥461,501,292.31, compared to ¥511,360,274.64 in Q1 2021, indicating improved cash management[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,636,175,441.87, down 8.82% from CNY 1,794,485,114.25 at the end of the previous year[5] - Total current liabilities decreased from ¥711,349,889.91 to ¥547,797,910.28, a reduction of about 22.9%[22] - Total liabilities amounted to CNY 581.85 million, a decrease from CNY 747.10 million year-over-year[26] - Total equity attributable to shareholders of the parent company was CNY 1,061.96 million, up from CNY 1,054.84 million in the previous year[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,530[16] - The largest shareholder, Pan Weichao, holds 37.54% of shares, totaling 80,602,574 shares, with 34,530,000 shares pledged[16] - The total number of shares held by the top ten unrestricted shareholders amounts to 37,150,000 shares[17] - The company has a total of 67,999,506 shares under lock-up due to executive restrictions[19] Government Support and Subsidies - The company received government subsidies amounting to CNY 1,275,779.04, contributing to other income of CNY 1,362,665.59, which increased by 319.78% year-on-year[13] Research and Development - Research and development expenses increased to CNY 33.01 million, up 14.0% from CNY 28.98 million in the previous year[26] Inventory and Accounts Receivable - The company experienced a 41.78% decrease in accounts receivable, totaling CNY 234,069,179.69, due to improved customer payment management[11] - Accounts receivable decreased significantly from ¥402,020,098.66 to ¥234,069,179.69, a reduction of about 41.8%[21] - The company reported a total of ¥200,454,047.96 in inventory at the end of the reporting period, down from ¥208,807,972.42[21] Production Costs and Profit Margins - The net profit margin was significantly impacted by increased production costs due to global supply chain issues and a strategic focus on core business areas[6]

Financial Performance - The company achieved operating revenue of 1,821.07 million yuan in 2021, representing a year-on-year growth of 36.23%[7] - The net profit attributable to shareholders was 8.87 million yuan, a decrease of 87.36% compared to the previous year[8] - The company's operating revenue for 2021 was CNY 1,821,072,459.44, representing a 36.23% increase compared to CNY 1,336,748,072.32 in 2020[27] - The net profit attributable to shareholders for 2021 was CNY 8,868,815.45, a decrease of 87.36% from CNY 70,161,749.27 in 2020[27] - The net profit after deducting non-recurring gains and losses was CNY 2,262,945.90, down 96.38% from CNY 62,530,323.99 in the previous year[27] - The net cash flow from operating activities was negative CNY 880,845.32, a decline of 101.13% compared to CNY 77,989,587.32 in 2020[27] - The total assets at the end of 2021 amounted to CNY 1,794,485,114.25, reflecting a 29.75% increase from CNY 1,383,062,978.39 at the end of 2020[27] - The net assets attributable to shareholders increased by 61.40% to CNY 1,054,835,727.20 from CNY 653,562,218.94 in 2020[27] - The basic earnings per share for 2021 was CNY 0.04, a decrease of 89.19% from CNY 0.37 in 2020[27] - The company reported a quarterly revenue of CNY 544,789,259.83 in Q4 2021, which was the highest among the four quarters[30] Research and Development - The company significantly increased its R&D investment during the reporting period, with a substantial rise compared to the previous year[8] - The company's R&D investment totaled 161.82 million CNY, accounting for 8.89% of revenue, with a year-on-year increase of 41.55%[68] - The R&D team consists of over 400 personnel, making up 19.77% of the total workforce, with multiple R&D centers established in various cities[68] - The company holds a total of 533 patents, including 86 invention patents, and has applied for 102 new patents during the reporting period[69] - The company has developed a standardized health management SaaS platform that connects various industry resources, aiming to reduce costs and enhance operational efficiency for clients[59] - The company is developing a series of smart portable blood pressure monitors aimed at special populations, with a focus on improving measurement accuracy for groups such as pregnant women and diabetics[104] - The company is developing a remote health management technology platform, aiming to create at least one smart product with this capability and secure a patent[108] - The wearable device project has entered the structural, electronic, and firmware design development stage, focusing on health management through lifestyle tracking[113] Market and Industry Trends - The remote health management market in China reached a scale of 314 billion RMB in 2020, with expectations to exceed 4 trillion RMB by 2030[39] - The global medical device market was valued at 493.5 billion USD in 2020, growing by 8.96% year-on-year[40] - China's medical device market size reached 772.1 billion RMB in 2020, with a year-on-year growth of 21.76%, and is projected to surpass 1 trillion RMB by 2022[40] - The health IoT and remote health management market is experiencing rapid growth due to increasing health awareness and aging population[39] - Chronic diseases are a major public health issue, with over 78% of elderly individuals suffering from at least one chronic condition, leading to nearly 70% of national health expenditure being attributed to chronic disease management[46] Strategic Focus and Future Plans - The company aims to enhance its global supply chain management capabilities and improve cost structure to boost profitability[8] - The company plans to focus on remote healthcare, home healthcare, primary healthcare, and chronic disease management for future product and technology innovations[8] - The company aims to leverage its strengths in smart health hardware and big data to become a world-class provider of health IoT and digital health services, focusing on health management verticals[54] - The company is actively pursuing digital transformation in health management, aligning with national strategies to enhance digital health services across various sectors including healthcare, insurance, and education[54] - The company plans to enhance user experience by integrating communication modules into its products, allowing for real-time health data visualization[110] Risk Management - The company faces risks from global chip shortages and rising raw material prices, which have adversely affected profit margins[7] - The company will strengthen its foreign exchange risk management to mitigate the impact of currency fluctuations on profitability[15] - The company emphasizes the need for improved management capabilities to match its rapid growth and expansion strategy[10] Corporate Governance and Management - The company is committed to improving its corporate governance structure to ensure sustainable development and compliance with regulatory requirements[88] - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholders[170] - The company maintains independence in its operations, personnel, and financial matters from its controlling shareholders[177] - The company has a diverse management team with backgrounds in various industries, including technology and law[196][197] - The company is focusing on maintaining stability in its board and management structure during the transition period[187] Shareholder Relations - The company will establish a broader, multi-level, and multi-channel communication system with the public and investors to enhance transparency and accuracy[165] - The company aims for synchronized growth in corporate value, shareholder value, and investor value[165] - The company has been actively engaging with institutional investors through online meetings to discuss overall business conditions and future capacity planning[166]